- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 31.07. | Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director | ||
| 30.07. | Moderna's LP.8.1-adapted COVID-19 vaccine recommended by CHMP | ||
| 30.07. | Havas Lynx appoints Ayesha Walawalkar as chief strategy officer | ||
| 29.07. | AstraZeneca's Imfinzi granted FDA priority review to treat early-stage gastric cancer | ||
| 29.07. | Roche shares promising data from Alzheimer's disease development portfolio | ||
| 28.07. | AbbVie's Elahere granted MHRA approval to treat platinum-resistant ovarian cancer | ||
| 28.07. | J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma | ||
| 25.07. | Novartis and Matchpoint enter inflammatory disease partnership worth $1bn | ||
| 25.07. | GSK's Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma | ||
| 25.07. | Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies | ||
| 24.07. | Johnson & Johnson's Darzalex approved by EC as first treatment for high-risk SMM | ||
| 24.07. | LEO's Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema | ||
| 24.07. | Abivax shares positive late-stage results for obefazimod in ulcerative colitis | ||
| 23.07. | AstraZeneca unveils plans to boost US footprint with $50bn investment | ||
| 23.07. | Roche's Itovebi granted EC approval to treat advanced breast cancer patients | ||
| 23.07. | NICE recommends ALK's immunotherapy to target underlying cause of hay fever | ||
| 23.07. | FDA appoints George Tidmarsh as director of CDER | ||
| 22.07. | Biogen to boost US manufacturing footprint with $2bn North Carolina investment | ||
| 22.07. | Eli Lilly/Almirall's Ebglyss shows promise in atopic dermatitis patients with darker skin tones | ||
| 22.07. | Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition | ||
| 21.07. | LEO Pharma gains access to Boehringer's skin disease drug for €90m upfront | ||
| 21.07. | AstraZeneca shares late-stage results for Tagrisso combination in lung cancer | ||
| 21.07. | EC approves SpringWorks Therapeutics' Ezmekly to treat rare genetic disorder NF1 | ||
| 18.07. | Johnson & Johnson's TAR-200 granted FDA priority review to treat bladder cancer | ||
| 18.07. | NICE recommends BeOne's Brukinsa to treat mantle cell lymphoma on NHS |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .